Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPURE TRANSPLANT
2024-517408-12-00Phase 3Authorised
- Sponsor
- CHRU Nancy
- Start
- Nov 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in end-stage kidney disease (ESKD) comparing Eplerenone arm with Placebo arm (2 arms). Primary endpoint: Iohexol clearance at 3 months. Planned start Nov 2024; status: authorised.
02
Drugs
eplerenone
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-517408-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517408-12-00.